10.3389/fimmu.2018.01213.s001
Timo Jan Oberstein
Timo Jan
Oberstein
Lava Taha
Lava
Taha
Philipp Spitzer
Philipp
Spitzer
Janina Hellstern
Janina
Hellstern
Martin Herrmann
Martin
Herrmann
Johannes Kornhuber
Johannes
Kornhuber
Juan Manuel Maler
Juan
Manuel Maler
image_1_Imbalance of Circulating Th17 and Regulatory T Cells in Alzheimer’s Disease: A Case Control Study.tif
Frontiers
2018
Th17
regulatory T cell
Th1
Alzheimer’s disease
mild cognitive impairment
Tau
amyloid beta
2018-06-04 04:10:32
Figure
https://frontiersin.figshare.com/articles/figure/image_1_Imbalance_of_Circulating_Th17_and_Regulatory_T_Cells_in_Alzheimer_s_Disease_A_Case_Control_Study_tif/6427493
<p>The neuropathological hallmarks of Alzheimer’s disease (AD), i.e., neuritic plaques and neurofibrillary tangles, consist of beta amyloid peptides (Aβ) and hyperphosphorylated Tau. These are accompanied by reactive microglia and astrocytes in the vicinity of the neuritic plaques and by changes to the peripheral immune system, e.g., an increase of the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α in the peripheral blood. To address a potential involvement of peripheral T helper cell (T<sub>h</sub>) subsets in AD, we conducted a case control study with 54 individuals with AD dementia (n = 14), with mild cognitive impairment (MCI) due to AD (MCI<sub>AD</sub>, n = 14), with MCI unlikely due to AD (MCI<sub>other</sub>, n = 13), and controls without cognitive impairment (controls, n = 13). The proportions of CD3<sup>+</sup>CD8<sup>−</sup>IL-17A<sup>+</sup>IFNγ<sup>−</sup> Th17 cells, CD3<sup>+</sup>CD8<sup>−</sup>IL-17A<sup>−</sup>IFNγ<sup>+</sup> Th1 cells, and CD4<sup>+</sup>CD127<sup>low</sup>CD25<sup>+</sup> regulatory T cells (T<sub>regs</sub>) were assessed by flow cytometry. In addition, the correlations of the proportions of T<sub>h</sub> subsets to cerebrospinal fluid biomarkers were studied. CD3<sup>+</sup>CD8<sup>−</sup>IL-17A<sup>+</sup>IFNγ<sup>−</sup> Th17 cells were significantly increased in subjects with MCI<sub>AD</sub> compared to age- and sex-matched subjects with MCI<sub>other</sub> and controls (MCI<sub>AD</sub> mean = 1.13, SD = 0.77; MCI<sub>other</sub> mean = 0.58, SD = 0.28; and controls mean = 0.52, SD = 0.22; p = 0.008). The proportion of CD4<sup>+</sup>CD127<sup>low</sup>CD25<sup>+</sup> T<sub>regs</sub> was not altered between the different groups, but it significantly positively related with the levels of total Tau and pTau181 (r<sub>Treg|totalTau</sub> = 0.43, p = 0.021, n = 28; r<sub>Treg|pTau181</sub> = 0.46; p = 0.024, n = 28) in subjects with AD but not in nonAD controls (r<sub>Treg|totalTau</sub> <sub>=</sub> −0.51, p = 0.007, n = 26). The increase of circulating CD3<sup>+</sup>CD8<sup>−</sup>IL-17A<sup>+</sup>IFNγ<sup>−</sup> Th17 cells in the early stages of AD and the association of CD4<sup>+</sup>CD127<sup>low</sup>CD25<sup>+</sup> T<sub>regs</sub> with neurodegeneration marker Tau may indicate that the adaptive immune system relates to neuropathological changes in AD.</p>